# A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.

> **NCT02011334** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 285 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT02011334
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011334, "A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02011334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*